THE ALIGN-AR TRIAL: Safety and Effectiveness/Performance of the Transfemoral JenaValve Pericardial TAVR System in the Treatment of Patients With Symptomatic Severe Aortic Regurgitation (AR)

Status: Active_not_recruiting
Location: See all (19) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

To collect information about treatment for severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aortic regurgitation may include fatigue and shortness of breath. The preferred treatment for severe aortic regurgitation is aortic valve replacement surgery.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient with severe aortic regurgitation (AR).

• Patient at high risk for open surgical valve replacement

• Patient symptomatic according to NYHA functional class II or higher

• The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB)/ Ethics Committee (EC) of the respective clinical site.

Locations
United States
California
Cedars Sinai Medical Center
Los Angeles
California Pacific Medical Center Research Institute
San Francisco
Washington, D.c.
MedStar Washington Hospital Center
Washington D.c.
Georgia
Emory University Hospital
Atlanta
Piedmont Healthcare
Atlanta
Michigan
University of Michigan
Ann Arbor
New York
New York-Presbyterian/ Columbia University Medical Center
New York
Texas
Baylor Scott & White Research Institute
Dallas
Washington
University of Washington
Seattle
Other Locations
Germany
Kerckhoff-Klinik GmbH Bad Nauheim
Bad Nauheim
Herz- und Diabeteszentrum NRW Ruhr-Universität Bochum Bad Oeynhausen
Bad Oeynhausen
Deutsches Herzzentrum Berlin
Berlin
Universitätsklinikum Bonn
Bonn
Herzzentrum der Universität zu Köln
Cologne
Universitätsklinikum Frankfurt
Frankfurt
Universitäres Herzzentrum Hamburg
Hamburg
Netherlands
Leiden University Medical Center
Leiden
St. Antonius Hospital
Nieuwegein
Erasmus University Medical Center
Rotterdam
Time Frame
Start Date: 2018-04-20
Completion Date: 2027-09-29
Participants
Target number of participants: 100
Treatments
Experimental: Transcatheter Aortic Valve Replacement (TAVR)
TAVR with JenaValve Pericardial Valve and Delivery System
Related Therapeutic Areas
Sponsors
Leads: JenaValve Technology, Inc.

This content was sourced from clinicaltrials.gov